32 results
6-K
LEGN
Legend Biotech Corporation
9 Aug 24
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
7:01am
in the sale to the customer under the Janssen Agreement.
Novartis License Agreement
On November 10, 2023, Legend Biotech, through its wholly owned
6-K
LEGN
Legend Biotech Corporation
20 Nov 23
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
6:02am
our pro-rata share of collaboration net trade sales for which Janssen Biotech, Inc. (“Janssen”) is the principal in the sale to the customer under
6-K
lx49ad
15 Aug 23
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
6:10am
6-K
EX-99.1
jxguq5r eab4jvfn0
14 Apr 23
Master Technology Transfer, Manufacturing and Clinical Supply Services Agreement for Bcma Car-t Product
8:30am
6-K
EX-99.1
lkrunjtj95 8j
3 Apr 23
Legend Biotech 6-K
4:01pm
6-K
EX-10.1
aosov qvp5nu
3 Oct 22
Legend Biotech Corporation 6-K
4:02pm
6-K
EX-10.1
ehvil
4 Aug 22
Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board
4:18pm
424B5
1k6 56wapq
27 Jul 22
Prospectus supplement for primary offering
4:32pm
424B5
4oswqpjc5
25 Jul 22
Prospectus supplement for primary offering
4:29pm
6-K
EX-99.3
fu5cousn p88otnkfgjn
25 Jul 22
Legend Biotech Corporation Announces Proposed Public Offering
4:07pm
6-K
EX-99.2
ftcnlgavljh4yh38igm
25 Jul 22
Legend Biotech Corporation Announces Proposed Public Offering
4:07pm
6-K
EX-99.3
szf3yy4gibyag8
14 Dec 21
Legend Biotech Corporation Announces Proposed Public Offering
4:27pm
6-K
EX-99.2
0hpo f3lpc164dwh1iw
14 Dec 21
Legend Biotech Corporation Announces Proposed Public Offering
4:27pm
6-K
EX-99.1
6zhki2vdk o6b9fu82
16 Nov 21
Legend Biotech Corp. 6-K
8:30am
6-K
wmjx 6midwjt0p0e5
23 Aug 21
Current report (foreign)
8:16am